Paper28629344
Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
Tanaka M and 4 others. BMC Musculoskelet Disord, 2017. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis. Papers, record 28629344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28629344
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Density | Major topic |
| Bone Density Conservation Agents | Major topic |
| Cathepsin K | Major topic |
| Osteoporosis, Postmenopausal | Major topic |
| Thiazolidines | Major topic |
| Aged | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/P020941/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8703060 | Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. | Science | 1996 | https://conductscience.org/library/papers/8703060 | PubMed |
| 2 | 16509577 | Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. | J Med Chem | 2006 | https://conductscience.org/library/papers/16509577 | PubMed |
| 3 | 22533981 | Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women. | Br J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22533981 | PubMed |
| 4 | 10968780 | Bone resorption by osteoclasts. | Science | 2000 | https://conductscience.org/library/papers/10968780 | PubMed |
| 5 | 15876399 | The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. | Adv Drug Deliv Rev | 2005 | https://conductscience.org/library/papers/15876399 | PubMed |
| 6 | 10968781 | Therapeutic approaches to bone diseases. | Science | 2000 | https://conductscience.org/library/papers/10968781 | PubMed |
| 7 | 12733725 | The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. | J Bone Miner Res | 2003 | https://conductscience.org/library/papers/12733725 | PubMed |
| 8 | 23013236 | Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. | Br J Clin Pharmacol | 2013 | https://conductscience.org/library/papers/23013236 | PubMed |
| 9 | 18248311 | The influence of circadian rhythms on the kinetics of drugs in humans. | Expert Opin Drug Metab Toxicol | 2008 | https://conductscience.org/library/papers/18248311 | PubMed |
| 10 | 12110413 | Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. | Bone | 2002 | https://conductscience.org/library/papers/12110413 | PubMed |
| 11 | 8288568 | Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. | J Biol Chem | 1994 | https://conductscience.org/library/papers/8288568 | PubMed |
| 12 | 8506892 | Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. | Am J Med | 1993 | https://conductscience.org/library/papers/8506892 | PubMed |
| 13 | 22113921 | Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. | J Bone Miner Res | 2012 | https://conductscience.org/library/papers/22113921 | PubMed |
| 14 | 10571690 | Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. | J Bone Miner Res | 1999 | https://conductscience.org/library/papers/10571690 | PubMed |
| 15 | 21380636 | Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. | Osteoporos Int | 2012 | https://conductscience.org/library/papers/21380636 | PubMed |
| 16 | 24915115 | Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. | J Clin Endocrinol Metab | 2014 | https://conductscience.org/library/papers/24915115 | PubMed |
| 17 | 9811821 | Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9811821 | PubMed |
| 18 | 26188109 | An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women. | Bone | 2015 | https://conductscience.org/library/papers/26188109 | PubMed |
| 19 | 18293146 | Clinical chronopharmacology in the elderly. | Chronobiol Int | 2008 | https://conductscience.org/library/papers/18293146 | PubMed |
| 20 | 21982869 | Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. | Bone | 2011 | https://conductscience.org/library/papers/21982869 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41607468 | Bidirectional crosstalk between the bone extracellular matrix and lysosomes in bone remodeling and osteoporosis. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41607468 | PubMed |
| 39957690 | Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health. | Curr Drug Targets | 2025 | https://conductscience.org/library/papers/39957690 | PubMed |
| 35912093 | Cathepsin K+ Non-Osteoclast Cells in the Skeletal System: Function, Models, Identity, and Therapeutic Implications. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/35912093 | PubMed |
| 35265628 | The Mechanosensory Role of Osteocytes and Implications for Bone Health and Disease States. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/35265628 | PubMed |
| 35163315 | Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad? | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163315 | PubMed |
| 34604343 | Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions - Part II. | Kidney Dis (Basel) | 2021 | https://conductscience.org/library/papers/34604343 | PubMed |
| 32582709 | Cathepsin K: The Action in and Beyond Bone. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32582709 | PubMed |
| 31980525 | Reassessing enzyme kinetics: Considering protease-as-substrate interactions in proteolytic networks. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/31980525 | PubMed |
| 30663085 | Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30663085 | PubMed |
| 29723068 | Advances in the discovery of cathepsin K inhibitors on bone resorption. | J Enzyme Inhib Med Chem | 2018 | https://conductscience.org/library/papers/29723068 | PubMed |
| 29721251 | Bone-targeted agents in multiple myeloma. | Hematol Rep | 2018 | https://conductscience.org/library/papers/29721251 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTSK | 1513 | PubTator's text mining | https://conductscience.org/library/genes/1513 | NCBI Gene |
| CYP27A1 | 1593 | PubTator's text mining | https://conductscience.org/library/genes/1593 | NCBI Gene |
| PTH | 5741 | PubTator's text mining | https://conductscience.org/library/genes/5741 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28629344
GET https://conductscience.org/api/papers/v1/28629344/references?page=2